^
1d
Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults. (PubMed, Cancers (Basel))
Although rare, myeloproliferative neoplasms can involve young patients and pose unique challenges for clinicians in diagnosis and therapy. The paper aims to review the biological markers of MPNs in pediatric populations-a particular group of patients that has been poorly studied due to the low frequency of MPN diagnosis.
Review • Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CALR (Calreticulin)
2d
Leukemia-mutated proteins PHF6 and PHIP form a chromatin complex that represses myeloid leukemia stemness. (PubMed, bioRxiv)
We show that PHIP loss phenocopies PHF6 loss, and that PHF6 requires PHIP to occupy chromatin and exert downstream transcriptional effects. Our work unifies PHF6 and PHIP, two disparate leukemia-mutated proteins, into a common functional complex that suppresses AML stemness.
Journal
|
PHF6 (PHD Finger Protein 6)
|
PHF6 mutation
2d
The Synchronous Diagnosis of Multiple Myeloma (MM) and Chronic Myeloid Leukemia (CML). (PubMed, Cureus)
Both cancers were aggressively treated. The patient received autologous stem cell transplantation (ASCT) for multiple myeloma and tyrosine kinase inhibitor for chronic myeloid leukemia concurrently to achieve the complete response.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
3d
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib (clinicaltrials.gov)
P=N/A, N=105, Recruiting, Samara State Medical University | Trial completion date: May 2023 --> Sep 2025 | Trial primary completion date: May 2023 --> Sep 2025
Trial completion date • Trial primary completion date
|
Bosulif (bosutinib)
4d
Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches. (PubMed, J Genet Eng Biotechnol)
Phellifuropyranone A and Meshimakobnol B show significant potency as inhibitors of the T315I-BCR::ABL1 mutant protein, comparable to ponatinib. These compounds may serve as effective alternatives or synergistic agents with ponatinib, potentially overcoming drug resistance and improving treatment outcomes in Chronic Myeloid Leukemia.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 T315I
|
Iclusig (ponatinib)
6d
Cancer and Aging Resilience Evaluation in Older Adults with Hematologic Malignancies: the CARE-Heme Registry (clinicaltrials.gov)
P=N/A, N=5000, Recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
6d
PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis. (PubMed, Adv Sci (Weinh))
Pharmacological inhibition of PRMT1 activity by MS023 remarkably eliminates LSCs and prolongs the survival of CML mice...PRMT1 augments the global protein synthesis via RPL29 in CML LSCs. Taken together, the findings provide new evidence that histone arginine methylation modification regulates protein synthesis in LSCs and highlight PRMT1 as a valuable druggable target for patients with CML.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PRMT1 (Protein Arginine Methyltransferase 1)
|
MS023
7d
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (clinicaltrials.gov)
P1, N=19, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; Administratively Complete
Trial termination
|
cytarabine • fludarabine IV • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate)
9d
BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. (PubMed, Cancer Sci)
Additionally, a label-free artificial intelligence-driven flow cytometry successfully identified not only the BCR::ABL1-transduced cells but also peripheral leukocytes from CML patients by assessing mitochondrial morphological alterations. These findings suggested the crucial role of BCR::ABL1-induced mitochondrial fragmentation in driving BCR::ABL1-positive cell proliferation, and the potential use of mitochondrial morphological alterations as a clinical biomarker for the label-free detection of CML cells.
Journal
|
ABL1 (ABL proto-oncogene 1)
10d
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma (clinicaltrials.gov)
P2, N=38, Completed, Zwi Berneman | Unknown status --> Completed
Trial completion
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • WT1 (WT1 Transcription Factor)
10d
Chemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing. (PubMed, Bioorg Chem)
Several second-generation tyrosine kinase inhibitors (2GTKIs), such as nilotinib, dasatinib, bosutinib, and radotinib (RTB), followed the groundbreaking introduction of imatinib. This review is the first attempt that extensively presents a compilation of data on RTB and describes its therapeutic potential against blood and solid tumors. Further investigations on RTB could expand its chemotherapeutic usage in various solid tumors and enhance the possibility of drug repurposing in cancer therapy.
Review • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
dasatinib • imatinib • Tasigna (nilotinib) • Bosulif (bosutinib) • Supect (radotinib)
10d
Progesterone decreases viability and up regulates membrane progesterone receptors expression on the human Chronic Myeloid Leukemia cell line. (PubMed, Cancer Genet)
Our findings showed that progesterone affects its receptor expression on K562 cells. Thus it may influence the performance of K562 cells in addition to its direct effects on these cells (via binding to its receptors).
Preclinical • Journal
|
PGR (Progesterone receptor)
10d
An MDS Patient with Deletion 20q and a t(9;22)(q34;q11.2): A Case Report and Review of the Literature. (PubMed, J Assoc Genet Technol)
The patient was started on nilotinib therapy...This case pinpoints the importance of comprehensive study when MDS is present with deletion 20q and a t(9;22), as it can be misdiagnosed as CML. While definitive therapeutic guidelines have yet to be established for this rare presentation of MDS, the use of tyrosine kinase inhibitors is under investigation.
Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 deletion
|
Tasigna (nilotinib)
11d
A Comprehensive Whole Genome Sequencing Assay Provides Robust Characterization of Clinically Relevant Genomic Alterations across Myeloid Malignancies Concordant with Matched Results from Targeted DNA, Whole Transcriptome RNA and Cytogenetic Profiling (ASH 2024)
Additionally, WGS can identify unique SVs that may be missed by conventional methods and enables clinical benefits such as HLA typing for potential transplant (alloHCT) or diagnostic refinement by retroviral insertion (e.g. HTLV-1). These findings demonstrate the potential for integration of WGS into clinical practice to enhance personalized treatment strategies.
Clinical • Discordant • Whole genome sequencing
|
FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
Tempus xT Assay • Tempus xR
12d
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations. (PubMed, Drugs)
For patients with AP-CML who progressed while on TKI therapy or those with BP-CML, alloHCT is considered the only curative therapy. Our goal is to review the available data on the therapy of patients with AP-CML and BP-CML.
Review • Journal • Metastases
|
ABL1 (ABL proto-oncogene 1)
13d
Exploring Inhibition Mechanisms in Wildtype and T315I BCR-ABL1: An In Silico Approach Integrating Virtual Screening, MD Simulations, and MM-GBSA Analysis. (PubMed, J Comput Chem)
The selected hit compounds showed ΔG scores ranging from -118.09 to -74.85 kJ/mol in both wildtype and mutant ABL1. Considering all in silico studies performed, it can be inferred that the identified molecules hold promise as potential candidates for drug design aimed at targeting CML.
Preclinical • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
ABL1 T315I
13d
COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity. (PubMed, Front Immunol)
The results showed that the level of BCR-ABL P210 was upregulated upon transfection of SARS-CoV-2 pseudovirus into blood samples of CML patients. Our results demonstrate that COVID-19 suppresses the immune activity and consequentially elevates the level of BCR-ABL P210 of CML patients.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD8 (cluster of differentiation 8)
13d
Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. (PubMed, Front Oncol)
After key baseline characteristics adjustment, cumulative BCR::ABL1 IS ≤1% and MMR rates were statistically higher with ponatinib than asciminib in patients without a baseline response in most of the comparisons by 12 months. Favorable efficacy outcomes observed in ponatinib vs. asciminib were consistently stronger in the T315I mutation subgroup.
Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 T315I
|
Iclusig (ponatinib) • Scemblix (asciminib)
14d
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. (PubMed, Int J Biol Macromol)
Moreover, CK2 inhibition or genetic ablation of the CK2α catalytic subunit sensitizes T315I-cells towards TKIs. Collectively, our results suggest the potential benefit of inhibiting CK2 in CML characterized by T315I-dependent resistance.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 T315I
15d
Diagnostic Ambiguity Caused by an Atypical e18a2 BCR::ABL1 Transcript in a Chronic Myeloid Leukemia Patient. (PubMed, Case Rep Hematol)
The use of a cryptic splice site in intron 1 of ABL1 led to the generation of an in-frame BCR::ABL1 fusion transcript. The diagnostic difficulties caused by this atypical variant and its implications for diagnostic routine are discussed.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
16d
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML (clinicaltrials.gov)
P1, N=16, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2024 --> Jun 2025
Trial completion date
|
Xpovio (selinexor)
16d
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
Opdivo (nivolumab) • cytarabine • azacitidine • Rydapt (midostaurin) • decitabine • ABP 206 (nivolumab biosimilar) • Starasid (cytarabine ocfosfate)
16d
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy. (PubMed, Front Immunol)
All in all, our results highlight NK cells and innate CD8 T-cells harboring cytotoxic content, as well as global downregulation of PD-1-expression on effector T-cells, as potential predictive functional signatures for successful TFR in CML. Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PRF1 (Perforin 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
|
PD-1 expression • CD8 expression
17d
BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using an FDA-approved droplet-based digital PCR assay. (PubMed, J Mol Diagn)
In addition, we observed that e13a2 and e14a2 BCR::ABL1 transcript types could be discriminated based on the mean fluorescence intensity of BCR::ABL1-positive droplets. BCR::ABL1 digital PCR is feasible for DMR quantification in clinical practice and offers an increased sensitivity over RT-qPCR.
FDA event • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Xpert® BCR-ABL Ultra
19d
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study. (PubMed, Ann Hematol)
These findings highlight dPCR as a sensitive and accurate tool for monitoring MRD in CML patients, providing information for treatment management decisions, and potentially enhancing the selection of candidates for treatment-free remission. Further standardization of dPCR methodologies is warranted to leverage their benefits in clinical practice.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
20d
MCC-20963: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (clinicaltrials.gov)
P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Apr 2025
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Inrebic (fedratinib)
21d
Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis. (PubMed, Pharmaceuticals (Basel))
Predictions of toxicological and pharmacokinetic properties (ADME/Tox) using the top100/base (600 structures), in comparison with the commercial drug imatinib, showed that only nine exhibited the desired properties...Considering future in vitro or in vivo assays, we elaborated the theoretical synthetic routes of the promising compounds identified in the present study. Based on our in silico findings, the selected ligands show promise for future studies in developing chronic myeloid leukemia treatments.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
22d
COHO: Critical Care Outcomes of Hematologic Oncology Patients (clinicaltrials.gov)
P=N/A, N=415, Active, not recruiting, Mount Sinai Hospital, Canada | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
22d
Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. (PubMed, Clin Lymphoma Myeloma Leuk)
Ponatinib discontinuation is feasible in patients with CML-CP failing prior TKIs. Patients who achieve sustained MR4.5 for at least 2 years have the highest likelihood of remaining in treatment-free remission following ponatinib discontinuation.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
Iclusig (ponatinib)
22d
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies. (PubMed, Bioorg Chem)
Furthermore discussed about the benefits, possible challenges, viewpoints, comparison with other targeted protein degraders (LYTACs, AUTOTACs) and the most current research results of PROTACs technology in multiple oncology therapies. Abbreviations: PROTACs, Proteolysis Targeting Chimeras; PK, Pharmacokinetic; PD, Pharmacodynamic; MetAP-2, (methionine aminopeptidase 2); BCL6, B-cell lymphoma 6; GCN5, General Control Nonderepressible 5; BKT, Bruton's tyrosine kinase; BET, Bromodomain and extra-terminal; AR, Androgen or Androgen receptor; ER, Estrogen or Estrogen receptor; FDA, Food and Drug Administration; mCRPC, Metastatic castration-resistant prostate cancer; STAT3, Signal Transducer and Activator of Transcription 3; FAK, Focal adhesion kinase; POI, Protein of interest; PEG, Polyethylene glycol; UPS, Ubiquitin-Proteasome System; VHL, Von Hippel-Lindau; CRBN, Cereblon; MDM2, Mouse Double Minute 2 homologue; cIAP, Cellular Inhibitor of Apoptosis; RNF, Ring Finger Protein; BRD, Bromodomain; CDK, Cyclin-dependent kinase; PAMPA, Parallel Artificial Membrane Permeability studies; BRET, Bioluminescence Resonance Energy Transfer; MCL, Mantle cell lymphoma; MCL-1, Myeloid Cell Leukemia 1; BCL-XL, B-cell lymphoma extra-large; TRK, Tropomyosin Receptor Kinase; RTKs, Transmembrane Receptor Tyrosine Kinase; NTRK, Neurotrophic Tyrosine Receptor Kinase; DHT, Dihydrotestosterone; EGFR, Epidermal Growth Factor Receptor; EGFR-TKIs, EGFR tyrosine kinase inhibitors; NSCLC, non-small cell lung cancer; BCR, B-cell receptor; CML, Chronic myelogenous leukemia; TKI, Tyrosine kinase inhibitors; MoA, Mechanism of action; TPD, Targetted protein degraders; LYTACs, Lysosome targeting chimeras; ASGPR, Asialoglycoprotein receptor; AUTOTACs, Autophagy-Targeting Chimeras; ATTECs, Autophagy-tethering compounds; CRISPR-Cas9, Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9; TALEN, Transcription Activator-Like Effector Nuclease; ZFN, Zinc Finger Nuclease.
Review • Journal
|
ER (Estrogen receptor) • AR (Androgen receptor) • MCL1 (Myeloid cell leukemia 1) • BCL6 (B-cell CLL/lymphoma 6) • BTK (Bruton Tyrosine Kinase) • BCL2L1 (BCL2-like 1) • CRBN (Cereblon) • MUC4 (Mucin 4, Cell Surface Associated) • NTRK (Neurotrophic receptor tyrosine kinase)
22d
Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells. (PubMed, Biomed Pharmacother)
This was achieved partially by inhibition of ABCG2-mediated excretion of dasatinib from CML cells. Therefore, these findings provide important insights for improving CML treatment and overcoming TKI resistance.
Journal
|
BCR (BCR Activator Of RhoGEF And GTPase) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
|
ABCG2 overexpression
|
dasatinib
23d
IIT PH1 KDS-1001 in Patients With CML (clinicaltrials.gov)
P1, N=0, Withdrawn, Duke University | N=12 --> 0 | Trial completion date: Sep 2027 --> Dec 2029 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2025 --> Dec 2027
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
SAR445419
23d
Navigating diagnostic dilemmas: a rare presentation of extramedullary T-lymphoblastic leukemia/lymphoma with chronic myeloid leukemia. (PubMed, J Hematop)
This case contributes to the medical literature by documenting a rare occurrence of extramedullary T-LBL with concurrent CML. The absence of a CML history makes the diagnosis particularly challenging and underscores the need for comprehensive and personalized treatment strategies.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 fusion
24d
Single-cell data revealed the function of natural killer cells and macrophage cells in chemotherapy tolerance in acute myeloid leukemia. (PubMed, PeerJ)
This study reveals the potential role of NK cells and macrophages in AML chemoresistance through the analysis of single-cell RNA sequencing data. This provides new ideas and insights into the key mechanisms of immune cells in AML treatment.
Journal
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • HLA-E (Major Histocompatibility Complex, Class I, E) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CCL3 (C-C Motif Chemokine Ligand 3) • KLRB1 (Killer Cell Lectin Like Receptor B1) • KLRC1 (Killer Cell Lectin Like Receptor C1) • LGALS9 (Galectin 9) • NKG2D (killer cell lectin like receptor K1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
26d
Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2. (PubMed, Mol Med)
The present analyses indicate that hyperoside can target the NRF2/SLC7A11/GPX4 axis to induce ferroptotic CML cell death.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
27d
The acetylglucosaminyltransferase GnT-Ⅲ regulates erythroid differentiation through ERK/MAPK signaling. (PubMed, J Biol Chem)
Furthermore, the lack of bisecting GlcNAc modification on c-Kit and transferrin receptor 1 (CD71) suppressed cellular signaling and accelerated the degradation of the CD71 protein, respectively. Our study highlights the critical role of MGAT3 in regulating erythroid differentiation associated with the ERK/MAPK signaling pathway, which may shed light on identifying new differentiation therapy in chronic myelogenous leukemia.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFRC
27d
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. (PubMed, JAMA Oncol)
Olverembatinib may provide a viable new treatment option for patients after failure of 2 or more TKIs. ClinicalTrials.gov Identifier: NCT04260022.
Clinical • P1 data • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
ABL1 T315I
|
Iclusig (ponatinib) • Scemblix (asciminib) • Nailike (olverembatinib)
29d
TGRX-326 Phase I Oral Pharmacokinetic Study (clinicaltrials.gov)
P1, N=72, Not yet recruiting, Shenzhen TargetRx, Inc.
New P1 trial
|
deulorlatinib (TGRX-326) • TGRX-678
29d
CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia. (PubMed, Heliyon)
Moreover, this increase disappears in CML patients after treatment with tyrosine kinase inhibitors when the curative effect was satisfactory. We conclude that an increase in the proportion of CD56briCD38+ neutrophil subsets exceeding 2.0 % of total neutrophils serves as a highly sensitive and specific flow cytometry marker, enabling rapid and accurate identification of CML.
Journal • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
BCR-ABL1 fusion • CD38 expression • NCAM1 expression
30d
NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
P2, N=35, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025
Enrollment change • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
1m
Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib. (PubMed, Mol Biol Rep)
The combination of MST-312 and imatinib shows potential as a CML therapy. However, further research and clinical trials are necessary to validate these findings and determine their clinical relevance.
Journal • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5)
|
BCL2 expression • MYC expression • TP53 expression • BAX expression
|
imatinib